QRG Capital Management Inc. Sells 8,945 Shares of Genmab A/S Sponsored ADR $GMAB

QRG Capital Management Inc. lessened its stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 12.0% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 65,902 shares of the company's stock after selling 8,945 shares during the quarter. QRG Capital Management Inc.'s holdings in Genmab A/S were worth $1,362,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Foresight Group Ltd Liability Partnership bought a new stake in Genmab A/S during the 1st quarter valued at approximately $954,000. Vident Advisory LLC bought a new stake in Genmab A/S during the 1st quarter valued at approximately $242,000. GAMMA Investing LLC boosted its stake in Genmab A/S by 1,465.3% during the 1st quarter. GAMMA Investing LLC now owns 33,482 shares of the company's stock valued at $656,000 after purchasing an additional 31,343 shares during the period. Fifth Third Bancorp boosted its stake in Genmab A/S by 16.6% during the 1st quarter. Fifth Third Bancorp now owns 42,151 shares of the company's stock valued at $825,000 after purchasing an additional 6,015 shares during the period. Finally, Parallel Advisors LLC boosted its stake in Genmab A/S by 377.5% during the 2nd quarter. Parallel Advisors LLC now owns 3,720 shares of the company's stock valued at $77,000 after purchasing an additional 2,941 shares during the period. Institutional investors own 7.07% of the company's stock.

Genmab A/S Trading Up 0.3%

Shares of GMAB opened at $32.74 on Thursday. Genmab A/S Sponsored ADR has a 1 year low of $17.24 and a 1 year high of $33.63. The stock has a 50 day simple moving average of $26.46 and a 200-day simple moving average of $22.69. The stock has a market cap of $21.02 billion, a PE ratio of 16.45, a PEG ratio of 1.84 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.39 by $0.15. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The business had revenue of $925.00 million during the quarter, compared to analysts' expectations of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Zacks Research upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, October 2nd. Wall Street Zen upgraded Genmab A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, September 26th. Truist Financial increased their target price on Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research note on Tuesday, July 8th. Weiss Ratings restated a "hold (c)" rating on shares of Genmab A/S in a research note on Wednesday. Finally, HC Wainwright upped their price target on Genmab A/S from $36.00 to $40.00 and gave the company a "buy" rating in a report on Thursday, October 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Genmab A/S presently has a consensus rating of "Moderate Buy" and an average target price of $40.80.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.